trending Market Intelligence /marketintelligence/en/news-insights/trending/OfXlkOpHzVXzFTr1GZOa0w2 content esgSubNav
In This List

Dechra to acquire minority stake in Medical Ethics

Blog

Insight Weekly: US inflation soars; real estate faces slowdown; megadeals drive tech M&A

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Insight Weekly: Path to net-zero; US manufacturing momentum; China's lithium M&A frenzy


Dechra to acquire minority stake in Medical Ethics

Dechra Pharmaceuticals PLC entered an A$18.0 million deal to acquire 33% of Medical Ethics Pty Ltd.

Medical Ethics is the parent company of Animal Ethics Pty. Ltd., which has sold the rights of its Tri-Solfen treatment to Dechra Pharmaceuticals for all regions except Australia and New Zealand.

Dechra will have a seat on the Medical Ethics board and minority shareholder rights.

Tri-Solfen is a painkiller used during routine treatments of farm animals such as castration, tail docking, debudding and dehorning.

As of March 30, US$1 was equivalent to A$1.30.